Currently, six pan-cancer biomarkers—NTRK, BRAF V600E, RET, HER2-positive, MSI-high, and TMB-high—along with nine molecularly targeted therapies have expanded treatment options across diverse malignancies. This evidence concerns the gene ERBB2 and cancer.